Severe Perampanel Toxicity in a Pediatric Patient With Prolonged Symptoms.

J Emerg Med

Division of Medical Toxicology, Department of Emergency Medicine, University of California at San Diego Medical Center, San Diego, CA.

Published: November 2021

Background: Perampanel is a new antiepileptic used to treat partial-onset seizures and generalized tonic-clonic seizures in people older than 12 years old. Perampanel is a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, with a prolonged half-life of approximately 105 hours. Few cases of significant toxicity have been reported, and effects in overdose are poorly understood.

Case Report: This case describes a 20-month-old healthy female who ingested 8 mg of perampanel. She presented to a pediatric emergency department 1 hour after ingestion with ataxia, irritability, and somnolence. Vital signs were: heart rate 130 beats per minute, blood pressure 112/97 mmHg, temperature 99°F, respiratory rate 30 breaths per minute. She was admitted to the pediatric intensive care unit. During the hospitalization, she developed hypotension and bradycardia which improved with stimulation and fluid resuscitation. Intermittent bradycardia persisted for 32 hours after ingestion. Physical examination was notable for somnolence and truncal ataxia with irritability when aroused, all of which improved throughout the hospitalization. A quantitative level obtained on hospital day 3 (HD) was 750ng/ml. On HD 3 the patient was noted to be ataxic but otherwise had an age-appropriate neurologic examination. She was discharged on HD 4 with normal vital signs, return to baseline mental status, and baseline gait. The patient's cardiovascular, neurologic, and behavioral symptoms were attributed to perampanel toxicity. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS ?: Toxicity from a perampanel overdose is poorly understood both in adults and pediatric patients with significant cardiovascular, behavioral, and central nervous system abnormalities.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jemermed.2021.07.011DOI Listing

Publication Analysis

Top Keywords

perampanel toxicity
8
ataxia irritability
8
vital signs
8
perampanel
5
severe perampanel
4
toxicity
4
pediatric
4
toxicity pediatric
4
pediatric patient
4
patient prolonged
4

Similar Publications

Phenobarbital use in pediatric perampanel overdose with coma, respiratory compromise.

Toxicol Rep

December 2024

University of Pittsburgh School of Medicine, Department of Critical Care Medicine, St Joseph's Children's Hospital, Tampa, FL, USA.

Article Synopsis
  • Perampanel (Fycompa) is an antiepileptic drug used to treat generalized seizures, but there's limited knowledge on how to handle overdoses, especially in kids.
  • A case study describes a pediatric patient who experienced severe symptoms, including respiratory failure and coma, after ingesting a high dose of perampanel.
  • Clinicians need to recognize overdose symptoms and be ready for immediate interventions like resuscitation, as there are no known reversal agents and the medication has a very long half-life of 105 hours.
View Article and Find Full Text PDF
Article Synopsis
  • - Type I Alexander disease is a severe neurological disorder that causes issues like seizures and developmental problems starting in early childhood, linked to a mutation in the GFAP gene.
  • - Although there's no cure, some treatments like ceftriaxone and amoxicillin have shown mild symptomatic improvement in patients by affecting glutamate levels in the brain.
  • - In a case study, a patient with severe irritability and seizures improved significantly after treatment with amoxicillin and perampanel, suggesting a potential role for glutamate-modulating drugs in treating this condition.
View Article and Find Full Text PDF
Article Synopsis
  • Recent advancements in HIV prevention highlight the effectiveness of pre- and post-exposure prophylaxis (PrEP and PEP), particularly in the context of new anti-seizure medications (ASMs) that have emerged since 2012.
  • The review discusses the potential drug interactions between PrEP/PEP and various ASMs, particularly focusing on enzyme-inducing ASMs that may lower the effectiveness of tenofovir-containing treatments, as well as the impact of ritonavir on lamotrigine levels.
  • Clinicians are encouraged to be aware of these interactions and side effects, such as osteopenia and gastrointestinal issues, to provide better care for patients who might be at risk for both seizures and HIV infection.
View Article and Find Full Text PDF

Effects of CYP3A4 genetic polymorphisms on the pharmacokinetics and efficacy of perampanel in Chinese pediatric patients with epilepsy.

Seizure

August 2024

Department of Pharmacy, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, 830001, China; Institute of Clinical Pharmacy of Xinjiang Uygur Autonomous Region, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, 830001, China. Electronic address:

Article Synopsis
  • This study investigates how variations in the CYP3A4 gene affect the levels and effectiveness of the epilepsy drug perampanel (PER) in Chinese children with epilepsy.
  • 102 pediatric patients were analyzed after maintaining consistent PER doses for 21 days, measuring drug concentrations and assessing seizure reduction rates.
  • The results indicate significant differences in drug concentrations based on genetic variations, with implications for both treatment efficacy and adverse effects, suggesting that CYP3A4 genetic profiles should be considered in prescribing PER.
View Article and Find Full Text PDF

Purpose: This study was the first to evaluate the effect of CYP3A5*3 gene polymorphisms on plasma concentration of perampanel (PER) in Chinese pediatric patients with epilepsy.

Methods: We enrolled 98 patients for this investigation. Plasma PER concentrations were measured using liquid chromatography-tandem mass spectrometry.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!